China Drug Approvals & Reimbursement
Search China drug approvals and reimbursement listings by generic name, Chinese name, brand, or approval number.
2026 catalogs published Nov 14, 2026·Effective Jan 1, 2027— 4 non-renewed negotiated drugs retain transition coverage through Jun 30, 2027
Latest verified changes
20 verified recordsLaunch sample covering 20 drugs across 2026 NRDL additions, 6-month transition removals, payment scope expansions, and Commercial List updates (2025 vs 2026).Sample scope & sources
| Drug | Change | Status | Effective | Source |
|---|---|---|---|---|
| Mazdutide 玛仕度肽 · 信尔美 | NRDL Added Newly added to 2026 NRDL Negotiated List (#30, Class B, price redacted *); restricted to adults with Type 2 Diabetes mellitus (weight management indication not reimbursed). | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.119 Verified 2026-11-20 |
| Relmacabtagene autoleucel 瑞基奥仑赛 · 倍诺达 | NRDL Added Newly added to 2026 NRDL Negotiated List (#297, Class B, *) across 3 lymphoma indications (r/r LBCL, r/r FL, r/r MCL); transitioned out of the 2025 Commercial List (#12). | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.149 Verified 2026-11-20 |
| Insulin icodec / Semaglutide 依柯胰岛素司美格鲁肽 | NRDL Added Newly added to 2026 NRDL Negotiated List (#18, Class B, *) for adult T2D inadequately controlled on basal insulin or GLP-1 receptor agonist. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.118 Verified 2026-11-20 |
| Zolbetuximab 佐妥昔单抗 · 威络益 | NRDL Added Newly added to 2026 NRDL Negotiated List (#287, Class B, *) for first-line CLDN18.2+ HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with chemo. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.148 Verified 2026-11-20 |
| Datopotamab deruxtecan 德达博妥单抗 · 达卓优 | NRDL Added Newly added to 2026 NRDL Negotiated List (#288, Class B, *) for adult HR+/HER2- unresectable or metastatic breast cancer after prior ET and ≥1L chemo. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.148 Verified 2026-11-20 |
| Sapropterin dihydrochloride 盐酸沙丙蝶呤 · 海普益 | NRDL Added Newly added to 2026 NRDL Negotiated List (#42, Class B, ¥62.00 per 100mg tablet) for BH4-deficiency HPA; transitioned from the 2025 Commercial List (#2). | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.120 Verified 2026-11-20 |
| Pamiparib 帕米帕利 · 百汇泽 | NRDL Removed (Transition) Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #256); 6-month transition period under original payment standard runs through Jun 30, 2027. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Transition → Jun 30, 2027 | NHSA · Section I(1) Transition Clause Verified 2026-11-20 |
| Beraprost sodium (sustained-release) 贝前列素钠缓释片 | NRDL Removed (Transition) Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #40); 6-month transition period under original payment standard runs through Jun 30, 2027. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Transition → Jun 30, 2027 | NHSA · Section I(1) Transition Clause Verified 2026-11-20 |
| Xiao'er Niuhuang Qingxin San 小儿牛黄清心散 | NRDL Removed (Transition) Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #20); 6-month transition period under original payment standard runs through Jun 30, 2027. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Transition → Jun 30, 2027 | NHSA · Section I(1) Transition Clause Verified 2026-11-20 |
| Shenlong Ningxin Capsules 参龙宁心胶囊 | NRDL Removed (Transition) Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #26); 6-month transition period under original payment standard runs through Jun 30, 2027. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 Transition → Jun 30, 2027 | NHSA · Section I(1) Transition Clause Verified 2026-11-20 |
| Dupilumab 度普利尤单抗 · 达必妥 | Payment Scope Changed Expanded from 1 indication (atopic dermatitis) in 2025 (#93) to 5 indications in 2026 (#104): added prurigo nodularis, asthma (≥6y), eosinophilic COPD, and bullous pemphigoid. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.126 Verified 2026-11-20 |
| Trastuzumab deruxtecan 德曲妥珠单抗 · 优赫得 | Payment Scope Changed Expanded from 2 breast cancer settings in 2025 (#228) to 7 indications in 2026 (#255), adding HR+ HER2-low/ultralow BC, neoadjuvant HER2+ BC, 2L/3L+ HER2+ gastric/GEJ, and HER2-mutant NSCLC. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.142 Verified 2026-11-20 |
| Sacituzumab tirumotecan 芦康沙妥珠单抗 · 佳泰莱 | Payment Scope Changed Expanded from 2 indications in 2025 (#252) to 4 indications in 2026 (#284), adding HR+/HER2- breast cancer (post-ET/chemo) and earlier post-EGFR-TKI non-squamous NSCLC. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.147 Verified 2026-11-20 |
| Ivosidenib 艾伏尼布 · 拓舒沃 | Payment Scope Changed Expanded beyond r/r IDH1-mutated AML in 2025 (#258) to add first-line newly diagnosed IDH1-mutated AML combined with azacitidine (age ≥75 or intensive-chemo ineligible) in 2026 (#298). | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.149 Verified 2026-11-20 |
| Eliglustat tartrate 酒石酸艾格司他 · 赛德佳 | Payment Scope Changed Expanded from adult Gaucher disease type 1 in 2025 (#38, ¥381.00) to add pediatric GD1 patients (age ≥6y, weight ≥15kg, ERT-stable) in 2026 (#41, ¥361.95 per 84mg capsule). | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.119 Verified 2026-11-20 |
| Lutetium (177Lu) vipivotide tetraxetan 镥[177Lu]特昔维匹肽 · 派威妥 | Commercial List Added Adult PSMA-positive mCRPC: (1) After progression on ARPI and eligible to delay chemotherapy; (2) After progression on ARPI and taxane-based chemotherapy. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.5 Verified 2026-11-20 |
| Tofersen 托夫生 · 凯盛迪 | Commercial List Added Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-20 |
| Eplontersen sodium 依普隆特生钠 · 万诺维 | Commercial List Added Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN). | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-20 |
| Inaticabtagene autoleucel 纳基奥仑赛 · 源瑞达 | Commercial List Expanded Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.3 Verified 2026-11-20 |
| Tazemetostat hydrobromide 氢溴酸他泽司他 · 达唯珂 | Commercial List Removed Listed in 2025 Commercial List (#16); not carried into the 2026 Commercial List or 2026 NRDL. | Announced · Effective Jan 1, 2027 | Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-20 |
Mazdutide玛仕度肽▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Newly added to 2026 NRDL Negotiated List (#30, Class B, price redacted *); restricted to adults with Type 2 Diabetes mellitus (weight management indication not reimbursed).
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Newly added to 2026 NRDL Negotiated List (#297, Class B, *) across 3 lymphoma indications (r/r LBCL, r/r FL, r/r MCL); transitioned out of the 2025 Commercial List (#12).
Insulin icodec / Semaglutide依柯胰岛素司美格鲁肽▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Newly added to 2026 NRDL Negotiated List (#18, Class B, *) for adult T2D inadequately controlled on basal insulin or GLP-1 receptor agonist.
Zolbetuximab佐妥昔单抗▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Newly added to 2026 NRDL Negotiated List (#287, Class B, *) for first-line CLDN18.2+ HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with chemo.
Datopotamab deruxtecan德达博妥单抗▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Newly added to 2026 NRDL Negotiated List (#288, Class B, *) for adult HR+/HER2- unresectable or metastatic breast cancer after prior ET and ≥1L chemo.
▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Newly added to 2026 NRDL Negotiated List (#42, Class B, ¥62.00 per 100mg tablet) for BH4-deficiency HPA; transitioned from the 2025 Commercial List (#2).
Pamiparib帕米帕利▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #256); 6-month transition period under original payment standard runs through Jun 30, 2027.
6-month transition period through Jun 30, 2027.
▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated #40); 6-month transition period under original payment standard runs through Jun 30, 2027.
6-month transition period through Jun 30, 2027.
Xiao'er Niuhuang Qingxin San小儿牛黄清心散▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #20); 6-month transition period under original payment standard runs through Jun 30, 2027.
6-month transition period through Jun 30, 2027.
▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Removed from 2026 NRDL after unsuccessful renewal (was 2025 Negotiated TCM #26); 6-month transition period under original payment standard runs through Jun 30, 2027.
6-month transition period through Jun 30, 2027.
Dupilumab度普利尤单抗▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Expanded from 1 indication (atopic dermatitis) in 2025 (#93) to 5 indications in 2026 (#104): added prurigo nodularis, asthma (≥6y), eosinophilic COPD, and bullous pemphigoid.
Trastuzumab deruxtecan德曲妥珠单抗▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Expanded from 2 breast cancer settings in 2025 (#228) to 7 indications in 2026 (#255), adding HR+ HER2-low/ultralow BC, neoadjuvant HER2+ BC, 2L/3L+ HER2+ gastric/GEJ, and HER2-mutant NSCLC.
Sacituzumab tirumotecan芦康沙妥珠单抗▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Expanded from 2 indications in 2025 (#252) to 4 indications in 2026 (#284), adding HR+/HER2- breast cancer (post-ET/chemo) and earlier post-EGFR-TKI non-squamous NSCLC.
Ivosidenib艾伏尼布▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Expanded beyond r/r IDH1-mutated AML in 2025 (#258) to add first-line newly diagnosed IDH1-mutated AML combined with azacitidine (age ≥75 or intensive-chemo ineligible) in 2026 (#298).
Eliglustat tartrate酒石酸艾格司他▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Expanded from adult Gaucher disease type 1 in 2025 (#38, ¥381.00) to add pediatric GD1 patients (age ≥6y, weight ≥15kg, ERT-stable) in 2026 (#41, ¥361.95 per 84mg capsule).
Lutetium (177Lu) vipivotide tetraxetan镥[177Lu]特昔维匹肽▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Adult PSMA-positive mCRPC: (1) After progression on ARPI and eligible to delay chemotherapy; (2) After progression on ARPI and taxane-based chemotherapy.
Tofersen托夫生▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
Eplontersen sodium依普隆特生钠▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.
Tazemetostat hydrobromide氢溴酸他泽司他▾Announced · Effective Jan 1, 2027Eff. Jan 1, 2027
Listed in 2025 Commercial List (#16); not carried into the 2026 Commercial List or 2026 NRDL.
2026 China NRDL Changes
Compare 2025 vs 2026 NRDL entries across additions, 6-month transition removals, and expanded payment scopes.
Commercial Insurance List
Review NHSA innovative therapies recommended for commercial health insurance, including brand, MAH, and validity dates.
Mazdutide (玛仕度肽)
See how 3 NMPA approval numbers (H20250036–38), weight management vs T2D labels, and 2026 NRDL #30 connect.